Topics:

University of Pittsburgh, Abbott Labs to Develop Ras Inhibitors

University of Pittsburgh, Abbott Labs to Develop Ras Inhibitors

PITTSBURGH--The University of Pittsburgh, through the research of investigators Saïd Sebti, PhD, and Andrew Hamilton, PhD, has entered into a research agreement with Abbott Laboratories to develop novel cancer drugs that block the activity of the ras oncogene.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.